A Nature Biotechnology report detailed how six proteomic clocks were integrated into a phase 2a clinical trial to support simultaneous geroprotective assessment. The design reflects an expanded biomarker strategy beyond traditional endpoints, using proteomic signals to quantify biological aging changes during intervention in a way intended to strengthen clinical interpretation.